Live
Endpoints NewsSeaport and Hemab file for IPOs, with Kailera expected to price soonIlluminaDoes Illumina (ILMN) Now Offer Value After A 61.7% One Year Rebound? - simplywall.stIlluminaIllumina (ILMN), Labcorp (LH) Expand Precision Oncology NGS Collaboration - Yahoo FinanceLonza NewsLonza Group AG stock (CH0013841017): Is its biopharma contract dominance strong enough to unlock new - AD HOC NEWSFierceBiotechGSK CEO's 'scientific courage' propels plans for medley of phase 3 trials for Hansoh-partnered ADCEndpoints NewsGSK plans five Phase 3 studies for gynecological cancer ADC from HansohIlluminaIllumina Inc. stock (US4523271090): Is its genomics leadership strong enough for long-term U.S. inve - AD HOC NEWSAgilentTRADE NEWS: Agilent Technologies to Demonstrate Leading-Edge RF/Microwave Design and Test Solutions - YahooThermo FisherIs Thermo Fisher Scientific (TMO) Pricing Look Stretched After Recent Share Price Rebound - simplywall.stIlluminaIs It Time To Reassess Illumina (ILMN) After Its 61.7% One Year Share Price Rebound - Yahoo FinanceThermo FisherWallace Advisory Group Reduces Stake in Thermo Fisher Scientific - National Today10x Genomics Blog10X Genomics Opens with 6.32% Gain, Outperforming S&P 500's 2.51% Increase - Markets Mojo
FierceBiotech Feb 27, 2026

'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process

'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process

Original
Body unavailable. Use the original source.

Directory

59 All